Mohammad Zamani1,2, Shaghayegh Alizadeh-Tabari1, Vahid Zamani3. 1. Student Research Committee, School of Medicine, Babol University of Medical Sciences, Babol, Iran. 2. Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. 3. Vice-Chancellery for Health, Babol University of Medical Sciences, Babol, Iran.
Abstract
BACKGROUND: Irritable bowel syndrome (IBS) is a common and potential disabling functional gastrointestinal disorder. Studies have revealed a possible association between IBS and psychological problems, such as anxiety and depression. Existing systematic reviews have addressed only the levels of anxiety or depression in patients with IBS. AIM: To investigate systematically the prevalence of anxiety or depression in IBS patients METHODS: A literature search was conducted using the related keywords from the bibliographic databases of Embase, PubMed, Scopus, Web of Science and POPLINE published until 1 January 2019 with no language restriction. Studies reporting the prevalence of anxiety/depressive symptoms/disorders in adult (≥15 years) IBS patients were evaluated. The pooled prevalence, odds ratio (OR) and 95% CI were calculated using stata software. RESULTS: A total of 14 926 articles were initially screened, and finally 73 papers were included. The prevalence rates of anxiety symptoms and disorders in IBS patients were 39.1% (95% CI: 32.4-45.8) and 23% (95% CI: 17.2-28.8) respectively. The ORs for anxiety symptoms and disorders in IBS patients compared with healthy subjects were 3.11 (95% CI: 2.43-3.98) and 2.52 (95% CI: 1.99-3.20) respectively. The prevalence estimates of depressive symptoms and disorders in IBS patients were 28.8% (95% CI: 23.6-34) and 23.3% (95% CI: 17.2-29.4) respectively. The ORs for depressive symptoms and disorders in IBS patients compared to healthy subjects were 3.04 (95% CI: 2.37-3.91) and 2.72 (95% CI: 2.45-3.02) respectively. CONCLUSION: Patients with IBS have a three-fold increased odds of either anxiety or depression, compared to healthy subjects.
BACKGROUND:Irritable bowel syndrome (IBS) is a common and potential disabling functional gastrointestinal disorder. Studies have revealed a possible association between IBS and psychological problems, such as anxiety and depression. Existing systematic reviews have addressed only the levels of anxiety or depression in patients with IBS. AIM: To investigate systematically the prevalence of anxiety or depression in IBSpatients METHODS: A literature search was conducted using the related keywords from the bibliographic databases of Embase, PubMed, Scopus, Web of Science and POPLINE published until 1 January 2019 with no language restriction. Studies reporting the prevalence of anxiety/depressive symptoms/disorders in adult (≥15 years) IBSpatients were evaluated. The pooled prevalence, odds ratio (OR) and 95% CI were calculated using stata software. RESULTS: A total of 14 926 articles were initially screened, and finally 73 papers were included. The prevalence rates of anxiety symptoms and disorders in IBSpatients were 39.1% (95% CI: 32.4-45.8) and 23% (95% CI: 17.2-28.8) respectively. The ORs for anxiety symptoms and disorders in IBSpatients compared with healthy subjects were 3.11 (95% CI: 2.43-3.98) and 2.52 (95% CI: 1.99-3.20) respectively. The prevalence estimates of depressive symptoms and disorders in IBSpatients were 28.8% (95% CI: 23.6-34) and 23.3% (95% CI: 17.2-29.4) respectively. The ORs for depressive symptoms and disorders in IBSpatients compared to healthy subjects were 3.04 (95% CI: 2.37-3.91) and 2.72 (95% CI: 2.45-3.02) respectively. CONCLUSION:Patients with IBS have a three-fold increased odds of either anxiety or depression, compared to healthy subjects.
Authors: Robert J Shulman; Mariella M Self; Danita I Czyzewski; Jerry Goldberg; Margaret Heitkemper Journal: J Pediatr Date: 2020-05-04 Impact factor: 4.406
Authors: Johanna T W Snijkers; Wendy van den Oever; Zsa Zsa R M Weerts; Lisa Vork; Zlatan Mujagic; Carsten Leue; Martine A M Hesselink; Joanna W Kruimel; Jean W M Muris; Roel M M Bogie; Ad A M Masclee; Daisy M A E Jonkers; Daniel Keszthelyi Journal: Neurogastroenterol Motil Date: 2021-05-03 Impact factor: 3.960